Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
78.98B
Market cap78.98B
Price-Earnings ratio
18.07
Price-Earnings ratio18.07
Dividend yield
0.48%
Dividend yield0.48%
Average volume
610.46K
Average volume610.46K
High today
$755.62
High today$755.62
Low today
$744.89
Low today$744.89
Open price
$751.48
Open price$751.48
Volume
181.18K
Volume181.18K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $747.19, giving the company a market capitalization of 78.98B. It carries a P/E multiple of 18.07 and pays a dividend yield of 47.8%.

During the trading session on 2026-04-22, Regeneron(REGN) shares reached a daily high of $755.62 and a low of $744.89. At a current price of $747.19, the stock is +0.3% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 181.18K, compared to an average daily volume of 610.46K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Simply Wall St 17h
Regeneron’s Lunsekimig Data Expand Immunology Story Beyond Dupixent Dependency

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive Phase 2 results for lunsekimig, a bispecific antibody, in moderate to severe asthma and chronic rhin...

Regeneron’s Lunsekimig Data Expand Immunology Story Beyond Dupixent Dependency
Nasdaq 19h
Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth

Key Points Moderna's innovative technology could help it establish itself as a leader in the vaccine market. Regeneron has an exciting lineup of candidates, i...

Got $2,000? These Biotech Stocks Are Worth Considering for Long-Term Growth
TipRanks 1d
Regeneron announces publication of Phase 3 NIMBLE trial results

Regeneron (REGN) Pharmaceuticals announced detailed results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myast...

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
22.6%
Sell
0%

More REGN News

Simply Wall St 2d
What Regeneron Pharmaceuticals's Expanded EU Pediatric Approval for Dupixent Means For Shareholders

Earlier this month, Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved Dupixent for moderate-to-severe chronic spontaneous urt...

What Regeneron Pharmaceuticals's Expanded EU Pediatric Approval for Dupixent Means For Shareholders
Simply Wall St 6d
Regeneron’s Dupixent Win And Telix Deal Add New Layers To Valuation

The European Commission approved Dupixent as the first targeted treatment for moderate to severe chronic spontaneous urticaria in children aged 2 to 11 across t...

Regeneron’s Dupixent Win And Telix Deal Add New Layers To Valuation
Simply Wall St 7d
A Look At Regeneron Pharmaceuticals Valuation After New Telix Radiopharmaceutical Collaboration

Regeneron Pharmaceuticals (REGN) just expanded its oncology reach through a new collaboration with Telix Pharmaceuticals to co-develop radiopharmaceutical thera...

A Look At Regeneron Pharmaceuticals Valuation After New Telix Radiopharmaceutical Collaboration

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.